Eyconis, Inc. Begins First-in-Human EYC-0305 Trial in Wet AMD
REDWOOD CITY, Calif., August 18, 2026 Eyconis, Inc. announced the initiation of OVERTURE, its first-in-human Phase 1b/2a clinical trial...
anti-VEGF
Advertisement
Outlook Therapeutics Targets U.S. Launch of FDA-Approved LYTENAVA
ISELIN, N.J., August 14, 2026 Outlook Therapeutics, Inc. is advancing preparations for the U.S. commercial launch of LYTENAVA™ (bevacizumab-vikg)...
Roche’s Susvimo Receives Positive CHMP Opinion for EU Approval
BASEL, Switzerland, July 24, 2026 Roche announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use...
Phanes Advances Spevatamig with Phase 2 PDAC Enrollment Complete
SAN DIEGO, June 22, 2026 Phanes Therapeutics, Inc. has announced the completion of patient enrollment in its Phase 2...
Samsung Bioepis and Harrow Strengthen SB11 Clinical Evidence
INCHEON, South Korea & NASHVILLE, Tenn., July 20, 2026 Samsung Bioepis Co., Ltd. and Harrow, Inc. have presented positive...
Advertisements
SystImmune Advances Oncology Portfolio with Iza-bren Approval
REDMOND, Wash., July 17, 2026 SystImmune Inc. announced that its parent company, Sichuan Biokin Pharmaceutical Co., Ltd., has received...
REGENXBIO Reports Positive Long-Term Gene Therapy Results
ROCKVILLE, Md., July 18, 2026 REGENXBIO Inc. has announced positive long-term clinical data for its investigational one-time gene therapy,...
4DMT Reports Positive 2-Year PRISM Phase 2b Data for 4D-150
EMERYVILLE, Calif., July 18, 2026 4D Molecular Therapeutics (4DMT) announced positive two-year results from its PRISM Phase 2b clinical...
Regeneron Wins FDA Nod for EYLEA HD Extended Dosing
TARRYTOWN, N.Y., April 2, 2026 Regeneron Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has...
Advertisement
